Hepatitis C virus (HCV) is an enveloped virus with a single stranded, plus-sense RNA genome (~9.6 kb) consisting of ~341-base 5' non-translated region (NTR), a single open reading frame encoding all virus-specific proteins (~3011 amino acids), and a 3' NTR.
The polyprotein is cleaved, co-and post-translationally by host and viral proteases to produce structural proteins (core and envelope glycoproteins (E1,E2)) and nonstructural (NS) components: p7; NS2-3 (protease); NS3 (serine protease and RNA helicase); NS4A; NS4B; NS5A and NS5B (RNA-dependent RNA polymerase, RdRp) 1;2 .
Transmission of HCV is typically by the parenteral route, persistent infections occur in 70-80% of acutely infected individuals, the majority of which will develop chronic hepatitis and will be at risk for cirrhosis, end-stage liver disease and/or hepatocellular carcinoma 3 . HCV is associated with 40-60% of chronic liver disease in the U.S. Of these patients, one third goes on to develop progressive fibrosis and cirrhosis 4 making hepatitis C the major disease leading to liver transplantation 5 .
HCV sequences are continually evolving during an infection due to the error-prone NS5B RdRp, which generates an estimated 10 -5 -10 -4 errors/nucleotide/replication cycle 6;7 , and the high production and clearance rate of the virus, estimated at ~10 12 virions/day 8 .
Consequentially, HCV exists as several closely related but distinct viruses within a host; referred to as a quasispecies population. Seven major genotypes (GT) (designated 1-7)
have been defined for HCV, differing from each other by ~30-35% over the complete genome 9;10 . The greatest genetic variability is observed in the E1 and E2 glycoproteins and the NS5A region 9 . This genetic diversity poses problems for vaccine development from the perspective of target antigens and the potential for escape from vaccineinduced immune responses. Immune escape has been shown directly and indirectly for natural infections in both T-cell [11] [12] [13] and B-cell [14] [15] [16] epitopes.
There is no licensed vaccine for HCV and prophylactic vaccine development has been hampered by the fact that the only animal model for pathogenesis or immune control of viral infection is the chimpanzee. This model has been highly important for understanding mechanisms of viral clearance and especially the role of T-cells in control of viral replication [17] [18] [19] [20] [21] . Based on clinical and chimpanzee studies demonstrating the role of T-cells in natural clearance, T-cell-based vaccines have received a great deal of focus, particularly given that these vaccines can target more conserved regions of HCV.
The data generated from chimpanzee vaccine studies is the most comprehensive available to asses the success or shortcomings of HCV vaccine approaches. However, the majority of studies have used small numbers of animals (1 to 6 per study) ( Table 1) .
We have employed statistical methodology to quantitatively examine the published data and compare the course of HCV infection in naïve; vaccinated and rechallenged animals.
The results from these analyses have been used to assess how well vaccines against HCV are functioning at controlling viral replication, which areas still require further investigation, and to establish biomarkers and parameters that could be used to assess the success of vaccines in the clinic.
Materials and Methods
Data Search and Inclusion Criteria: Searches of the Scopus database (www.scopus.com) using the terms "hepatitis C virus" and "chimpanzee" or "hepatitis C virus" and "chimpanzee" and "vaccine" resulted in 341 and 93 publications, respectively.
These were reviewed and, where available, data was extracted on i) peak HCV RNA titer (the highest titer following infection) (ii) time to peak titer (representing the day postinfection at which viral replication is controlled) (iii) duration of viremia (the time from infection until viremia was consistently undetectable) and (iv) outcome of infection 
Results

Primary and Secondary HCV Infections:
We initially analyzed matched data on viral kinetics during primary and secondary infections of recovered chimpanzees. We performed pairwise comparisons of peak RNA titers, time to peak titer and duration of viremia in 11 animals. Figure 1 shows that for each of these parameters the differences between primary and secondary infections are significant (P<0.004). The median peak RNA titer (log 10 RNA copies/mL) ( Figure 1A ) was significantly different between primary and secondary infections (p=0.0038); median difference of 2.0 log 10 (Interquartile Range (IQR) =1.2). The median peak RNA titer for primary infections was calculated as 5.9
(IQR=0.5), and for secondary infections as 4.0 (IQR=1.7). The median difference in time post infection that this peak titer was measured ( Figure 1B ) was also significant (p=0.0037); occurring earlier during secondary infections (13 days; IQR=12) compared to primary infections (56 days; IQR=26); median difference of 42 days (IQR=14).
Similarly, the duration of viremia ( Figure 1C ) was shortened significantly (p=0.0038) during secondary infections from 84 days (IQR=75) to 21 days (IQR=33); median difference 63 days, (IQR=38). Although persistent infections can occur in chimpanzees upon rechallenge 27;49;51 this was not observed in any of the animals for which paired data was available.
Evaluation of Vaccine Efficacy:
The type of immune control induced by natural infection with HCV could be taken as the minimum standard expected of any prophylactic vaccine. In order to assess how successful HCV vaccine trials have been in the chimpanzee model we compared peak viral RNA titer; time to peak titer and duration between naïve, rechallenged and vaccinated chimpanzees. Data from all studies listed in Table 1 were included in the statistical analyses. The studies performed by Houghton and co-workers 52;53 and Esumi et al 54 did not include data for RNA titers therefore these studies were excluded from our statistical comparisons of viral kinetics but were included in analyses of clearance rates.
HCV RNA Kinetics Independent of Outcome: Data obtained comparing peak titer and time to peak titer for the 3 groups of animals is shown in Figure 2 . All animals for which kinetics data were available were included in this comparison regardless of infection outcome (persistence or clearance). As expected from the pairwise comparisons performed for Figure 1 there is a significant decrease (P<0.001) for these two parameters in rechallenged animals compared to naïve animals. The median values for each parameter were similar to those seen for paired data. Specifically, 5.8 (IQR=1.1) and 4.6 (IQR=1.1) for peak RNA titer (log 10 RNA copies/mL) and 49 days (IQR=42) and 14 days (IQR=14) for peak date in naïve and rechallenged animals, respectively. More encouraging is the fact that we found significant decreases (P<0.001) for each parameter in vaccinated animals compared to naïve animals, median values for peak titer and peak date in vaccinated animals were 4.6 log 10 RNA copies/mL (IQR=1.4) and 21days (IQR=21), respectively. There was no significant difference in peak RNA titers (P=0.312; Figure 2A ) or control of viral replication (P=0.160; Figure 2B ) between rechallenged and vaccinated animals.
HCV RNA Kinetics Based on Outcome:
We performed the same statistical analyses using data only from naïve (n=24); rechallenged (n=28) and vaccinated (n=21) animals that cleared HCV with additional analysis to assess whether vaccination reduces the duration of viremia. Comparisons of peak titer and time to peak titer show significant decreases for rechallenged (P<0.0001) and vaccinated animals (P≤0.005) compared to naïve animals ( Figure 3 ), similar to that seen when all animals are included ( Figure 2 ).
The median values for peak titer in naïve, rechallenged and vaccinated animals were to naïve animals (61.9%) ( Table 2 ). The data also shows the rate of clearance in vaccinees is similar to rechallenged animals (16.7%) (P=0.214). However, if the proportion of persistent infections in vaccinated animals is analyzed with respect to the regions targeted, structural region alone compared to NS region alone or in addition to structural proteins, a different picture emerges. We find that a significantly (P=0.015) higher proportion of persistent infections (45.8%) are found when antigens to NS proteins are included in the vaccine (Table 3 ). The proportion of chronic infections in animals that receive vaccines targeting only the structural region (13.8%) is similar to that seen in rechallenged animals (16.7%, Table 2 ) while the proportion of chronic infections in animals that received vaccine containing NS components (Table 3;45.8%) is not significantly different (P=0.227) from naïve animals ( Table 2; 61.9%). there is a trend (P=0.08) for the recall response in vaccinated animals that cleared HCV (3.1; IQR=0.9) to be higher than that in vaccinated animals that developed persistent infections (2.8; IQR=0.8) ( Figure 4D ). These data further suggest that the magnitude of the vaccine-induced T-cell response cannot be used to predict success of a vaccine and that within vaccinees the quality of the response possibly accounts for more efficient proliferation of cells upon exposure to virus that then leads to clearance.
T-cell Responses at Challenge do not Predict
Discussion
This meta-analysis provides important data for future development, expectations and assessment of HCV prophylactic vaccines. We show statistically significant differences in viral kinetics between primary and secondary infections in recovered chimpanzees.
This statistical analysis is consistent with previous observations demonstrating that although infection can occur upon re-exposure following clearance, viral kinetics are very different with rapid clearance in the majority of cases 18;48;55;56 . Similar significant decreases in maximum HCV RNA titer and duration of infection for secondary infections in intravenous drug users were recently reported 57 . Interestingly, in both chimpanzees (Table 2 ) and humans 57 the HCV clearance rate was 83% of reinfected subjects, this compares to ~25% in patients 57 and ~38% in chimpanzees (Table 2) All of the chimpanzee vaccine approaches listed in Table 1 Ideally, the goal of prophylactic vaccines is to prevent infection upon exposure.
However, from our data analysis sterilizing immunity seems to be unrealistic for hepatitis 
